Results 51 to 60 of about 24,049 (149)

Data from Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab

open access: gold, 2023
Rajiv Raja   +6 more
openalex   +1 more source

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

open access: green, 2022
Alex K. Bryant   +7 more
openalex   +2 more sources

Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer

open access: green, 2022
Ting Xu   +12 more
openalex   +2 more sources

Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors [PDF]

open access: gold, 2023
Jonathan W. Goldman   +16 more
openalex   +1 more source

Extracellular matrix-myCAF signatures correlate with resistance to neoadjuvant aPD-L1 immune checkpoint inhibition with durvalumab + metformin in HPV+ HNSCC [PDF]

open access: hybrid
Pablo Llerena   +32 more
openalex   +1 more source

Supplementary Table from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

open access: gold, 2023
Martin H. Voss   +12 more
openalex   +1 more source

Predictive factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer [PDF]

open access: green, 2021
Hiroshi Mayahara   +12 more
openalex   +1 more source

Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

open access: gold, 2023
Kim Blenman   +19 more
openalex   +1 more source

Home - About - Disclaimer - Privacy